

MEDI-CAPS LIMITED

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231

Pithampur - 454775, Dist. Dhar

Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Web site:- www.medicaps.com

MCL/SE/2020-2021

Date: 10th November, 2020

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai – 400001(M.H.)

BSE Scrip Code: 523144

Subject: Submission of the Revised Cash flow Statements for the Quarter/Half Year ended on 30th September, 2020 as per Regulation 33(3) of SEBI (LODR) Regulations, 2015.

Dear Sir/Madam,

This is in Continuation of our letter no. MCL/SE/2020-2021 dated 6th Nov., 2020 regarding submission of Standalone as well as Consolidated Unaudited Quarterly/Half yearly Financial Results for the Quarter/Half Year ended on 30th September, 2020.

Pursuant to regulation 33(3)(d) of SEBI (LODR) Regulation, 2015, the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report thereon by Statutory Auditors for the Quarter/Half year ended 30th Sept., 2020 along with the Statement of Assets and Liabilities and Cash Flow Statement in the PDF Format which was approved by the Audit committee and the Board of Directors at their meeting held on 06.11.2020 have been submitted within prescribed time.

We would like to draw kind attention that, there is a printing error in the Cash flow statement submitted in PDF mode to the exchange on 6th November, 2020 for half year ended 30.09.2020.

Therefore we hereby once again submit the Revised Cash Flow Statement along with the Standalone and Consolidated Financial Result, Limited Review Report and Statement of Assets & Liabilities for quarter/half year ended 30.09.2020 for your ready reference.


Further we would like to further inform that we would also re-submit the corrected cash flow statement in XBRL mode.

You are requested to please take the same on record.

Thanking You,
Yours Faithfully,

For **MEDI-CAPS LIMITED**

ALOK K. GARG
MANAGING DIRECTOR
DIN: 00274321



Encl.: 1)-Revised Cash flows statement along with standalone and consolidated financial result, limited review report and statement of assets and liabilities for half year/quarter ended. 30.09.2020.

Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,
Opposite UCO Bank Indore (M.P.) 452001
Contact No: 0731-4028148

LIMITED REVIEW REPORT ON UNAUDITED STANDALONE QUARTERLY FINANCIAL RESULTS OF MEDI-CAPS LIMITED

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

1. We have reviewed the accompanying Unaudited Standalone Financial Results of **MEDI-CAPS LIMITED** ("the Company"), for the Quarter ended September 30, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim financial reporting "IND AS 34" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

2. We conducted our review of the statement in accordance with the Standard on review engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



4. On 21st Nov., 2019, the company announced to permanently discontinue Company's operations related to production/manufacturing of Hard Gelatin Capsule Shell in the plant situated at Mhow - Neemuch Road, Sector 1, Pithampur - 454775, Distt. Dhar. The discontinuation is consistent with the Company's long-term strategy to focus its activities in the areas of Real Estate Business and to divest unrelated activities. Accordingly, Loss for the quarter ended September 30, 2020 is from discontinuing operation of Rs 5.14 lakhs.

Place: Indore

Date: 06/11/2020

UDIN: 20429040AAAAEI3314

For: Rawka & Associates
(Chartered Accountants)



A handwritten signature in black ink, appearing to be "Venus Rawka", with a date "11/11" written below it.

Venus Rawka
(Partner)
M. No. 429040
FRN: 021606C


Independent Auditor's Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**TO THE BOARD OF DIRECTORS OF
Medi-Caps Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Medi-Caps Limited** and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiary for the quarter ended 30/09/2020 and for the period from 01/07/2020 to 30/09/2020, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30/09/2020 and the corresponding period from 01/07/2020 to 30/09/2020, as reported in these financial results have been approved by the Parent's Board of Directors.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.


4. The Statement includes the results of its subsidiary Medgel Private Limited.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consolidated review report of its subsidiary, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Our conclusion is not modified in respect of this matter.
7. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of Medgel Private Limited (subsidiary) which have not been reviewed/audited by their auditors, whose interim consolidated financial statements/ financial information/ financial results reflect total revenue of Rs. 1487.20 Lakhs, total net profit/(loss) after tax of Rs. 307.24 Lakhs and total comprehensive income of Rs. 52.56 Lakhs for the quarter ended 30/09/2020, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter

Place: Indore
Date: 06/11/2020
UDIN: 20429040AAAAEJ3986

For: Rawka & Associates
Chartered Accountants






Anus Rawka
(Partner)
M.No. 429040
FRN: 021606C

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-424242, Fax: 07292-407387
 Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

STATEMENT OF STANDALONE & CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER 2020

Sr. No.	Particulars	Rs.in Lacs							Consolidated				
		3 Months ended on 30.09.2020 (Unaudited)	3 Months ended on 30.06.2020 (Unaudited)	3 Months ended on 30.09.2019 (Unaudited)	6 Months ended on 30.09.2020 (Unaudited)	6 Months ended on 30.09.2019 (Unaudited)	Previous Year ended on 31.03.2020 (Audited)	3 Months ended on 30.09.2020 (Unaudited)	3 Months ended on 30.06.2020 (Unaudited)	3 Months ended on 30.09.2019 (Unaudited)	6 Months ended on 30.09.2020 (Unaudited)	6 Months ended on 30.09.2019 (Unaudited)	Previous Year ended on 31.03.2020 (Audited)
I	Income from operations												
	(a) Net sales	0.00	0.00	369.29	0.00	832.21	1090.85	1476.59	1202.82	1284.07	2679.41	2861.97	4305.20
	(b) Other operating income	0.00	0.00	17.57	0.00	37.81	56.39	7.00	17.01	17.57	24.01	37.81	227.49
I	Total income from operation	0.00	0.00	386.86	0.00	870.02	1147.44	1483.58	1219.83	1301.64	2703.41	2899.78	4532.70
II	Other Income	0.00	0.00	3.31	0.00	3.31	55.15	3.62	28.20	-124.38	31.82	-107.05	59.53
III	Total income (I+II)	0.00	0.00	390.17	0.00	873.33	1202.59	1487.20	1248.03	1177.26	2735.23	2792.74	4592.24
IV	Expenses												
	a) Cost of material consumed	0.00	0.00	220.03	0.00	420.32	541.03	833.70	549.70	613.24	1383.40	1513.85	2232.80
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	214.21	0.00	209.67	452.75	-141.42	23.26	178.02	-118.16	194.69	449.65
	d) Employee benefits expense	0.00	0.00	98.84	0.00	225.99	588.21	171.49	132.87	220.48	304.36	460.97	1103.77
	e) Finance costs	0.00	0.00	0.24	0.00	0.50	0.86	0.00	0.00	0.33	0.00	0.63	1.69
	f) Power Cost	0.00	0.00	74.75	0.00	155.91	194.67	66.18	50.97		117.15		374.76
	g) Depreciation and amortisation expense	0.00	0.00	7.92	0.00	16.98	35.54	37.31	37.31	44.69	74.62	90.52	183.01
	h) Other expenses	0.00	0.00	91.00	0.00	154.42	221.36	207.58	215.75	344.32	423.33	690.03	830.90
	Total Expenses (IV)	0.00	0.00	706.99	0.00	1183.79	2034.42	1174.83	1009.86	1401.10	2184.69	2950.70	5176.58
V	Profit / (Loss) before exceptional item & tax (III-IV)	0.00	0.00	-316.82	0.00	-310.46	-831.83	312.37	238.17	-223.83	550.54	-157.97	-584.34
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit/ (Loss) before tax (V-VI)	0.00	0.00	-316.82	0.00	-310.46	-831.83	312.37	238.17	-223.83	550.54	-157.97	-584.35
VIII	Tax expense												
	a) Current Tax	0.00	0.00	0.00	0.00	2.00	0.00	0.00	0.00	0.00	0.00	2.00	0.00
	b) Deferred Tax	0.00	0.00	1.64	0.00	1.64	0.84	0.00	0.00	1.64	0.00	1.64	0.84
	Total Tax Expenses	0.00	0.00	1.64	0.00	3.64	0.84	0.00	0.00	1.64	0.00	3.64	0.84
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	0.00	0.00	-318.46	0.00	-314.10	-832.67	312.38	238.17	-225.47	550.54	-161.61	-585.19
X	Profit/(loss) from discontinued operations	-5.14	-27.45	0.00	-32.59	0.00	0.00	0.00	-27.45	0.00	-32.59	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-5.14	-27.45	0.00	-32.59	0.00	0.00	-5.14	-27.45	0.00	-32.59	0.00	0.00
XIII	Profit/(loss) for the period (IX+XII)	-5.14	-27.45	-318.46	-32.59	-314.10	-832.67	307.24	210.72	-225.47	517.96	-161.61	-585.19
XIV	Other comprehensive income												
	(a) (i) items that will not be reclassified to statement of profit & loss	24.29	33.17	21.38	57.46	123.09	66.41	52.56	73.10	33.34	125.66	168.90	120.30
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	19.15	5.72	-297.08	24.87	-191.01	-766.26	359.80	283.82	-192.13	643.62	7.29	-464.89
XVI	Paid-up equity share capital of the company (Face value Rs.10/- Per Share)	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00





XVII	Reserves excluding revaluation reserves	0	0	0	0	0	4737.52	0.00	0.00	0.00	0.00	0.00	7848.45
XVIII	Earnings per equity share (for continuing operation)												
	a) Basic	0.19	0.05	-2.38	0.46	-1.53	-6.14	2.93	2.28	-1.54	5.42	0.06	-3.73
	a) Diluted	0.19	0.05	-2.38	0.46	-1.53	-6.14	2.93	2.28	-1.54	5.42	0.06	-3.73
XIX	Earnings per equity share (for discontinued operation)												
	a) Basic	-0.04	0.00	0.00	-0.26	0.00	0.00	-0.04	0.05	0.00	-0.26	0.00	0.00
	a) Diluted	-0.04	0.00	0.00	-0.26	0.00	0.00	-0.04	0.05	0.00	-0.26	0.00	0.00
XX	Earnings per equity share (for discontinued and continuing operation)												
	a) Basic	0.15	0.05	-2.38	0.20	-1.53	-6.14	2.89	2.32	-1.54	5.16	0.06	-3.73
	a) Diluted	0.15	0.05	-2.38	0.20	-1.53	-6.14	2.89	2.32	-1.54	5.16	0.06	-3.73



Segmentwise Revenue, Results and Capital Employed for Half Year Ended 30th September, 2020

(Amount in Lakhs)



S.N.	Segment Revenue	Quarter Ended		Half Year Ended		Year Ended
		Sept., 30, 2020	Sept., 30, 2019	Sept., 30, 2020	Sept., 30, 2019	Mar., 31, 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue					
	Pharma Division	1,476.59	1,284.07	2,679.41	2,861.97	4,575.48
	Real Estate Division	0.00		0.00	0.00	0.00
	Other	0.00		0.00	0.00	0.00
	Gross Turnover	1,476.59	1,284.07	2,679.41	2,861.97	4,575.48
2	Segment Results					
	Pharma Division	312.04	(226.18)	549.85	(161.18)	(599.42)
	Real Estate Division	0.00	0.00	0.00	0.00	0.00
	Other	0.00	0.00	0.00	0.00	0.00
	Total Segment Profit Before Tax	312.04	(226.18)	549.85	(161.18)	(599.42)
	Interest Income	0.34	1.04	0.70	2.20	16.76
	Interest Expenses	0.00	0.33	0.00	0.63	1.69
	Other Unallocable Income net of Expenditure	0.00	0.00	0.00	0.00	0.00
	Profit Before Tax	312.38	(225.47)	550.54	(159.61)	(584.35)
	Provision for current tax	0.00	0.00	0.00	2.00	0.00
	Item Related Earlier Year	0.00	0.00	0.00	0.00	0.00
	Profit After Tax	312.38	(225.47)	550.54	(161.61)	(584.35)




3	Capital Employed					
	Segment Assets (A)					
	Pharma Division	10,666.54	10,353.13	10,666.54	10,353.13	9,521.06
	Real Estate Division	25.00	0.00	25.00	0.00	0.00
	Other					
	Total (A)	10,691.54	10,353.13	10,691.54	10,353.13	
	Segment Liabilities (B)					
	Pharma Division	927.88	952.77	927.88	952.77	425.61
	Real Estate Division	25.00	0.00	25.00	0.00	0.00
	Other			0.00	0.00	
	Total (B)	952.88	952.77	952.88	952.77	
4	Total Capital Employed (Segment Assets-Segment Liabilities)					
	Pharma Division	9,738.66	9,400.36	9,738.66	9,400.36	9,095.45
	Real Estate Division	0.00		0.00		0.00
	Other			0.00		
	Total Capital Employed (Segment Assets-Segment Liabilities)	9,738.66	9,400.36	9,738.66	9,400.36	9,095.45



		(Rs. in Lacs)			
2	The standalone and Consolidated Statement of Assets & Liabilities is as under:	Standalone		Consolidated	
	Particulars	As at		As at	
		6 Month ended on 30/09/2020	12 Month ended on 31/03/2020	6 Month ended on 30/09/2020	12 Month ended on 31/03/2020
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I.	Assets				
(1)	Non-Current Assets				
	(a) Property, Plant and Equipment	321.17	362.97	5720.07	5826.16
	(b) Capital work-in-progress	0.00	0.00		
	(c) Investment Property	0.00	0.00	0.00	0.00
	(d) Financial Assets				
	(i) Investments	4581.43	4547.35	424.51	345.60
	(e) Other non-current assets	5.15	5.16	36.59	36.60
(2)	Current assets				
	(a) Inventories	32.28	53.26	795.48	544.62
	(b) Financial Assets				
	(i) Investments	691.39	668.09	2020.30	1851.64
	(ii) Trade receivables	249.20	266.48	601.40	440.59
	(iii) Cash and cash equivalents	0.16	0.02	0.24	0.16
	(iv) Bank balances other than (iii) above	92.52	74.50	674.48	125.12
	(c) Other current assets	176.96	177.62	418.47	350.56
	Total Assets	6150.26	6155.46	10691.54	9521.06
II.	EQUITY AND LIABILITIES				
	EQUITY				
	(a) Equity Share Capital	1247.00	1247.00	1247.00	1247.00
	(b) Other Equity	4762.39	4737.52	8491.66	7848.45
	LIABILITIES				
(1)	Non-Current Liabilities				
	(a) Financial Liabilities	0.00	0.00	0.00	0.00
	(i) Borrowings	3.24	0.54	3.24	0.00
	(b) Provisions	25.00	25.00	45.00	45.00



	(c) Deferred tax liabilities (Net)	43.20	43.20	43.61	43.20
(2)	Current Liabilities				
	(a) Financial Liabilities	0.00	0.00	0.00	0.00
	(i) Borrowings	0.00	6.35	0.00	6.35
	(ii) Trade payables	30.10	42.22	643.63	194.77
	a) total outstanding dues of micro enterprises and small enterprises; and				
	b) total outstanding dues of creditor other than micro enterprises and small enterprises;				
	(iii) Other financial liabilities (other than those specified in item (b),	0.00	0.00	0.00	0.00
	(b) Other current liabilities	39.33	54.18	217.41	136.30
	(c) Provisions	0.00	0.00		
	(d) Current Tax Liabilities (Net)	0.00	0.00	0.00	0.00
	Total Equity and Liabilities	6150.26	6155.46	10691.54	9521.06



Revised Standalone and Consolidated Cash Flow Statement for the quarter/half year ended Sept. 30, 2020				
PARTICULARS	Standalone		Consolidated	
	(Rs. In Lacs)			
	30 th Sept. 2020	30 th Sept. 2019	30 th Sept. 2020	30 th Sept. 2019
A. Cash Flow from Operating Activities				
Net Profit before Tax & Extraordinary Items	0	(314.09)	550.54	(161.62)
Adjustment For:				
Depreciation	0	16.98	74.62	90.52
Dividend Income	0	0	0	0
Other Comprehensive Income	0	0	68.20	0
Operating Profit before Working Capital Change	0	(297.11)	693.37	(71.09)
Adjustment for Working Capital				
(Increase)/ Decrease in Sundry Debtors	0	41.95	(178.09)	(25.81)
(Increase)/ Decrease in Inventories	0	244.78	(271.84)	154.31
(Increase)/ Decrease in Loans & Advances	0	39.84	(68.57)	(21.02)
Increase/(Decrease) in Current Liabilities & Provisions	0	(70.21)	556.93	(136.23)
Cash Generated from Working Capital	0	256.36	38.43	(28.75)
Cash generated from Operation	0	(40.75)	731.80	(99.84)
Income Tax for the year	0	0	0	0
Net cash Flow from Operating Activity	0	(40.75)	731.80	(99.84)
B. Cash Flow from Investing Activities				
Sale/(Purchase) of Investments	0	(34.68)	(10.32)	(59.75)
Purchase of Fixed Assets	0	(34.34)	(190.20)	(36.08)
Dividend Received	0	0	0	0
Discontinue Operation	(6.84)	0	(6.84)	0
Net Cash used in Investing Activities	(6.84)	(69.03)	(207.36)	(95.82)






C. Cash Flow from Financial Activities				
Increase in Short term Bank Borrowings	0	0	0	0
Proceeds from Long Term Borrowings	25	(1.20)	25	(1.20)
Net Cash Used in Financial Activities	25	(1.20)	25	(1.20)
Net Increase in Cash and Cash Equivalents (A+B+C)	18.16	(110.97)	549.44	(196.86)
Cash & Cash Equivalents at the Beginning of the year	74.52	212.92	125.28	248.22
Closing of the year	92.68	101.94	674.72	51.37
Increase in Cash and Cash Equivalents	18.16	(110.98)	549.44	(196.85)

1. The above standalone and consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 6th November, 2020. The Unaudited standalone & Consolidated financial results for the quarter and half year ended 30th September, 2020 have been subjected to limited review by the statutory auditors, who have expressed an unmodified opinion.
2. The financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.
3. The above consolidated financial result for the quarter ended 30th September 2020 includes the result of wholly owned subsidiary company MEDGEL PRIVATE LIMITED
4. Previous period/year figures have been regrouped wherever found necessary, to conform to current period / year classification.
5. There was no major impact of COVID-19, as company had already been discontinued the manufacturing activities since November, 2019. However due to COVID-19 various approval from statutory authorities for real estate project is delayed.
6. As per Ind AS 108 Operating Segments, if a single financial report contains both consolidated financial statements and the standalone financial statements of the Parent Company. Segment information may be presented on the basis of the consolidated financial statements. After discontinuation of pharma business, the company has entered into Real Estate Business for which the company has applied for various licensees and approval from various government departments which are pending for approval. Thus disclosure required by regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 on segment information is given in consolidated financial results from this quarter.
7. The earnings per share (basic and diluted) for the interim periods have not been annualized.
8. The aforesaid Un-audited financial results will be uploaded on the Company's website www.medicaps.com and will also be available on the website of the Stock Exchange i.e. www.bseindia.com for the benefit of shareholders and investors.
9. Description of Income & Expenditure of Discontinue Operation

Particulars	3 Month Ended Sep-30	6 Month Ended Sep-30	3 Month Ended Jun-30
I Income from operations	0	0	0
II Other Income	34.43	45.07	10.64
III Total income (I+II)	34.43	45.07	10.64
IV Expenses			
c) Changes in Inventories of finished goods, & work in progress	19.92	20.45	0.53
d) Employee benefits expense	1.95	6.58	4.63
e) Finance Cost	0.10	0.23	0.13
g) Depreciation expense	9.05	18.11	9.06





h) Other expenses	8.54	32.28	23.74
Total Expenses (IV)	39.56	77.65	38.09
Net Loss From Discontinue Operation	-5.13	-32.59	-27.45

10. Cash Flow of Discontinue Operation for the halfyear ended 30.09.2020

		30.09.2020
PARTICULARS		Amt (In lakhs)
A. Cash Flow from Operating Activities		
Net Profit before Tax & Extraordinary Items		-33
Adjustment For:		
Depreciation		18
Other Comprehensive Income		57
Operating profit before working capital change		42
Adjustment for Working Capital		
(Increase)/ Decrease in Sundry Debtors		17
(Increase)/ Decrease in Inventories		21
(Increase)/ Decrease in Loans & Advances		1
Increase/(Decrease) in Current Liabilities & Provisions		-27
		12
Cash generated from Operation		54
B. Cash Flow from Investing Activities		
Sale/(Purchase) of Investments		-57
Purchase of Fixed Assets		24
Net Cash used in Investing Activities		-34
C. Cash Flow from Financial Activities		
Increase in Short term Bank Borrowings		-3
Proceeds from Long term Borrowings		-25
Net Cash Used in Financial Activities		-28
Net Increase in Cash and Cash Equivalents (A+B+C)		-8

Place : INDORE
Date : 06/11/2020

For MEDICAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321
